Novavax (NVAX) Liabilities from Discontinued Operations (2025)
Novavax (NVAX) recorded quarterly Liabilities from Discontinued Operations of 47869000.0 in Q4 2025, down 6.93% quarter-over-quarter from 51435000.0 in Q3 2025.
Novavax (NVAX) Liabilities from Discontinued Operations (2025) Analysis & Trends
Novavax's Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 47869000.0 for Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations changed N/A year-over-year to 47869000.0; the TTM figure through Dec 2025 stood at 47869000.0 (changed N/A YoY), while the FY2025 annual figure was 47869000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was 47869000.0 for Q4 2025 at Novavax, down from 51435000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 51435000.0 in Q3 2025 to a low of 47869000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 47.87 Mn |
| Dec 31, 2025 | 47.87 Mn |
| Sep 30, 2025 | 51.44 Mn |
| Sep 30, 2025 | 51.44 Mn |